BCL11A

Across TCGA pan-cancer cohorts, BCL11A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCL11A data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BCL11A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BCL11A expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where BCL11A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.982	0.906	.010	14	view →
PDAC	OS	Tertile	All	0.268	0.684	.008	13	view →
LUAD	OS	Tertile	II,III,IV	0.262	0.829	.038	2	view →
HNSC	OS	Median	II,III,IV	1.000	0.948	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCL11A–LSCC (DFS)

Open the LSCC breakdown →